---
title: "Teva Canada Signs Agreement with Novartis to Commercialize Mayzent for MS Patients"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274518158.md"
datetime: "2026-02-02T13:05:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274518158.md)
  - [en](https://longbridge.com/en/news/274518158.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274518158.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274518158.md) | [English](https://longbridge.com/en/news/274518158.md)


# Teva Canada Signs Agreement with Novartis to Commercialize Mayzent for MS Patients

Teva Canada Limited has announced a new commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. for Mayzent® (siponimod), an oral treatment for secondary progressive multiple sclerosis (SPMS) with active disease. Under the agreement, Teva Canada will take on exclusive responsibility for the promotion, distribution, and commercialization of Mayzent® in Canada. The partnership aims to ensure continued access to Mayzent® for Canadian patients and healthcare professionals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via CNW (Ref. ID: C5864) on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [Novartis AG (NOT.DE)](https://longbridge.com/zh-HK/quote/NOT.DE.md)
- [NOVARTIS AG (NVS.US)](https://longbridge.com/zh-HK/quote/NVS.US.md)
- [Teva Pharmaceutical Industries (TEVA.US)](https://longbridge.com/zh-HK/quote/TEVA.US.md)

## 相關資訊與研究

- [Novartis Agrees To Acquire Excellergy, Inc.](https://longbridge.com/zh-HK/news/280735969.md)
- [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/zh-HK/news/281026919.md)
- [Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis | QNTM Stock News](https://longbridge.com/zh-HK/news/281013402.md)
- [Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis](https://longbridge.com/zh-HK/news/281370207.md)
- [Cresco Labs Awarded Texas Medical Cannabis License | CRLBF Stock News](https://longbridge.com/zh-HK/news/281563592.md)